Drug Trial Radar · NCT04042402
Long Term Extension Study in Patients With Primary Hyperoxaluria
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Jul 9, 2019
Primary completion
Apr 1, 2030
Study completion Apr 1, 2030
Sponsor
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyIndustry
- Sponsor type
- Industry
- First posted
- Aug 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.
Conditions
- Primary Hyperoxaluria Type 1 (PH1)
- Primary Hyperoxaluria Type 2 (PH2)
- Kidney Diseases
- Urologic Diseases
- Genetic Disease
- Primary Hyperoxaluria Type 3 (PH3)
Interventions
DCR-PHXCDrug
Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The annual rate of decline in eGFR in participants with PH1Time frame: Annual change from baseline
Locations
23 sites in 13 countries. Site status is shown where the registry gives one.
Clinical Research Site
San Francisco, California
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
New York, New York
Clinical Trial Site
Melbourne, Australia
Clinical Research Site
Herston, Queensland, Australia
Clinical Research Site
Hamilton, Ontario, Canada
Clinical Trial Site
Bron, France
Clinical Trial Site
Paris, France
Clinical Trial Site
Bonn, Germany
Clinical Trial Site
Heidelberg, Germany
Clinical Research Site
Roma, Italy
Clinical Trial Site
Fukuoka, Japan
Clinical Trial Site
Nagoya, Japan
Clinical Trial Site
Tokyo, Japan
Clinical Trial Site
Beirut, Lebanon
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
Tromsø, Norway
Clinical Research Site
Barcelona, Spain
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Ankara, Turkey (Türkiye)
Clinical Trial Site
Birmingham, United Kingdom
Clinical Trial Site
Hampstead, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.